| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8afd09a95e6a84ec29366a8252e98a5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L5-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L2-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L2-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L13-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L13-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23B4-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L27-10 |
| filingDate |
2006-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4691462dbcb77895469d5af0cf99463b |
| publicationDate |
2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008292637-A1 |
| titleOfInvention |
Therapeutic Uses of A3 Adenosine Receptor Antibodies |
| abstract |
The present invention concerns the use of an anti-A3 adenosine receptor (A3AR) immunoglobulin-based molecule for the preparation of a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3 adenosine receptor. Further provided by the invention is a method of treating a pathological condition associated with a high level of expression of A3 adenosine receptor in a subject, the method comprising administering to said subject an amount of the anti-A3AR immunoglobulin-based molecule, the amount being effective to treat or prevent said pathological condition. Finally, the present invention provides a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3AR comprising a physiologically acceptable carrier and the anti A3AR immunoglobulin-based molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015166654-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10961530-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11267868-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10919953-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013045943-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10253100-B2 |
| priorityDate |
2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |